Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02722941 · OUTCOME

Overall Survival (OS)

Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) · Source last updated 2022-11-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
at 2 years

What was measured

OS: The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.

Groups in this outcome

Cohort A: Maintenance Therapy

Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule. Panobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.

Cohort B: Maintenance Therapy

Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule. Panobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort A: Maintenance Therapy15
Cohort B: Maintenance Therapy15

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort A: Maintenance Therapy100Not reportedNANAfirst OS event occurred after 24 months
Cohort B: Maintenance Therapy100Not reportedNANAfirst OS event occurred after 24 months
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        first OS event occurred after 24 months
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        100
      2. comment
        first OS event occurred after 24 months
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        100
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    2. group Id
      OG001
      value
      15
    units
    Participants
description
OS: The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
dispersion Type
95% Confidence Interval
groups
  1. description
    Panobinostat (LBH589): 20 mg by mouth three (3) times per week, every other week, of a 28-day schedule. Panobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.
    id
    OG000
    title
    Cohort A: Maintenance Therapy
  2. description
    Panobinostat (LBH589): 10 mg by mouth daily for seven (7) days, every other week, of a 28-day schedule. Panobinostat: Maintenance therapy dosing as outlined in Cohorts A and B.
    id
    OG001
    title
    Cohort B: Maintenance Therapy
param Type
MEDIAN
reporting Status
POSTED
time Frame
at 2 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice